Gene News and Research

Latest Gene News and Research

New research on spinal muscular atrophy

Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences, researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."

8 Jun 2011

BPA affects development of uterus in female primates

Exposure in the womb to bisphenol A (BPA), a chemical widely used in the food and medical industries, causes changes in female primates' uterus development, new research suggests. The results will be presented Tuesday at The Endocrine Society's 93rd Annual Meeting in Boston.

8 Jun 2011

Scientists discover four different bacteria that can live on caffeine

As it turns out, humans aren't the only organisms that turn to caffeine for a pick-me-up. University of Iowa scientists have identified four different bacteria that actually can live on caffeine.

8 Jun 2011

Apple peel reduces muscle atrophy and promotes muscle growth in mice

For Popeye, spinach was the key to extra muscle. For the mice in a new University of Iowa study, it was apples, or more precisely a waxy substance called ursolic acid that's found in apple peel.

8 Jun 2011

Eating at wrong time of the day reduces fertility in fruit flies

Dieticians will tell you it isn't healthy to eat late at night: it's a recipe for weight gain. In fruit flies, at least, there's another consequence: reduced fertility.

8 Jun 2011

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

DxTerity Diagnostics announced today that it has acquired intellectual property rights to several blood based cancer diagnostic tests from SourceMDx Inc.

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Researchers in the Department of Pathology at Stony Brook University School of Medicine have discovered a laboratory method to expand adult hematopoietic stem cells (HSCs) using the SALL4 gene. Professor Yupo Ma, M.D., Ph.D., Lead Author, and colleagues used this method to produce a more than 10,000-fold increase in HSCs derived from normal human bone marrow.

7 Jun 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

Non-steroidal, oral contraceptive for men

Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.

7 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

Constellation raises $15M in Series B extension financing

Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

Gene News and Research

Latest Gene News and Research

New research on spinal muscular atrophy

BPA affects development of uterus in female primates

Scientists discover four different bacteria that can live on caffeine

Apple peel reduces muscle atrophy and promotes muscle growth in mice

Eating at wrong time of the day reduces fertility in fruit flies

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Increased blood clotting tendency linked to elevated bowel cancer risk

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Non-steroidal, oral contraceptive for men

Tikcro reports net loss of $30,000 for first quarter 2011

Constellation raises $15M in Series B extension financing

New gene therapy may cure Type 1 diabetes

Cancer risk assessment in Lynch syndrome

Global gene therapy market to reach $300 million by 2015

eBook: Using iPSCs models for human disease research and drug discovery eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering